Highlights from the PRAC Meeting 9-12 January 2017
At its monthly meeting, the EMA’s Pharmacovigilance Risk Assessment Committee discussed two ongoing safety reviews: Factor VIII and Retinoid-containing medicinal products. The Committee did not start or conclude a referral. The PRAC also focused on the broad range of its responsibilities which cover all aspects of the risk management of the use of medicines.
